Reconstitution of the lipid-linked oligosaccharide pathway for assembly of high-mannose N-glycans

Sheng-Tao Li¹, Tian-Tian Lu¹, Xin-Xin Xu¹, Yi Ding¹, Zijie Li¹, Toshihiko Kitajima¹, Neta Dean², Ning Wang¹ and Xiao-Dong Gao¹

1. Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education; School of Biotechnology, Jiangnan University, Wuxi 214122, China

2. Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York 11794-5215, USA

Correspondence and requests for materials should be addressed X.-D.G. (email: xdgao@jiangnan.edu.cn) or N.W. (email: wangning@jiangnan.edu.cn)

These authors contributed equally: Sheng-Tao Li, Tian-Tian Lu
Abstract

The asparagine (N)-linked Man9GlcNAc2 is required for glycoprotein folding and secretion. Understanding how its structure contributes to these functions has been stymied by our inability to produce this glycan as a homogenous structure of sufficient quantities for study. Here, we report the high yield chemoenzymatic synthesis of Man9GlcNAc2 and its biosynthetic intermediates by reconstituting the eukaryotic lipid-linked oligosaccharide (LLO) pathway. Endoplasmic reticulum mannosyltransferases (MTases) are expressed in *E. coli* and used for mannosylation of the dolichol mimic, phytanyl pyrophosphate GlcNAc2. These recombinant MTases recognize unique substrates and when combined, synthesize end products that precisely mimic those *in vivo*, demonstrating that ordered assembly of LLO is due to the strict enzyme substrate specificity. Indeed, non-physiological glycans are produced only when the luminal MTases are challenged with cytosolic substrates. Reconstitution of the LLO pathway to synthesize Man9GlcNAc2 *in vitro* provides an important tool for functional studies of the N-linked glycoprotein biosynthesis pathway.
Introduction

N-linked glycosylation is an essential modification that regulates protein structure and function\textsuperscript{1,2}. The N-linked glycan is processed very differently in species-, tissue- and cell-specific ways, leading to an immensely complex glycome. Despite their heterogeneity, most of N-glycans share a common Glc3Man9GlcNAc2 precursor oligosaccharide that is pre-assembled on the ER membrane before it is transferred to protein. Fourteen mono-saccharides are sequentially added onto a dolichyl pyrophosphate (PP-Dol) membrane anchor by ER membrane-associated Alg (asparagine-linked glycosylation) glycosyltransferases (GTases)\textsuperscript{3}. Once assembled, the Glc3Man9GlcNAc2 oligosaccharide is transferred to the target protein by oligosaccharyltransferase (OST), which catalyzes the formation of an N-glycosidic bond to an asparagine within the Asn-X-(Ser/Thr) consensus sequence\textsuperscript{3,4}. After its transfer, Glc3Man9GlcNAc2 is modified by removal or re-addition of glucoses under the regulation of the calnexin-calreticulin cycle. Production of deglucosylated protein-bound Man9GlcNAc2 (M9GN2) is the signal that tells the cell a glycoprotein has acquired its native conformation\textsuperscript{5,6}, and hence is competent to exit the ER for further cell-type specific glycosylation in the Golgi. Errors in the synthesis, transfer, or modification of the N-linked glycan causes glycoproteins to be recognized by quality control systems, preventing their exit from the ER and targeting them for degradation\textsuperscript{7-9}. Its critical position at the junction of glycoprotein folding, quality control, and transport from the ER underscores the importance of understanding the molecular details of M9GN2 for a range of biological and pharmacological studies, including glycan arrays\textsuperscript{10,11}, vaccine production\textsuperscript{12,13}, and glycoprotein quality control\textsuperscript{14,15}.

In eukaryotic cells, stepwise assembly of M9GN2 occurs on the ER membrane in two topologically distinct set of reactions (Figure 1)\textsuperscript{3}. First, on the cytosolic face, the Alg7/Alg13/Alg14 complex adds two N-acetylglucosamines from uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) to make dolichyl pyrophosphate GlcNAc2 (GN2-PP-Dol)\textsuperscript{16-21}. The Alg1, Alg2 and Alg11 mannosyltransferases (MTases) then add five mannoses from guanosine diphosphate mannose (GDP-Man) to make Man5GlcNAc2 (M5GN2-PP-Dol)\textsuperscript{22-26}. Second, after M5GN2-PP-Dol is flipped from the cytosolic face of the ER into the lumen, four additional mannoses are added by the Alg3, Alg9 and Alg12 MTases to form M9GN2-PP-Dol (Figure 1)\textsuperscript{27-30}. In contrast to the cytosolic mannosylations of M5GN2 that use
GDP-Man as sugar donor, the luminal mannosylations use dolichyl phosphate mannose, whose synthesis is catalyzed by dolichol phosphate mannose synthase (Dpm1, Figure 1)\textsuperscript{31}. Thus, biosynthesis of M9GN2-PP-Dol requires expression of nine different Alg GTases and three different donor sugar substrates.

Much effort has been devoted to the production of structurally homogenous M9GN2 substrate in amounts sufficient for functional and structural studies\textsuperscript{32-34}. Isolation of M9GN2 from natural sources (i.e. egg yolk and soybean) is limited by low recovery\textsuperscript{35,36}. Chemical synthesis of various high-mannose N-glycans has also been accomplished, resulting in higher yields but is labor-intensive and time-consuming\textsuperscript{37-40}. Chemoenzymatic synthesis using LLO substrates with simplified lipids has proved useful for producing some M9GN2 precursors, including M3GN2 and M5GN2\textsuperscript{25,41-44}. However, full length lipid-linked M9GN2 production has thus far been limited by its enzymatic complexity, which requires purification of a lipid carrier, various sugar donors and all the Alg MTases.

Here, we overcome these challenges and describe efficient production of full length M9GN2 oligosaccharide \textit{in vitro} using recombinant Alg proteins expressed from \textit{E. coli}. Reconstitution of the entire LLO pathway from GlcNAc2 to M9GN2 is achieved in two successive one-pot reactions, which correspond to the reactions that occur on the cytosolic and on the luminal faces of the ER \textit{in vivo}.
Results

Chemo-enzymatic synthesis of M5GN2

We previously reported efficient synthesis of the M3GN2 intermediate oligosaccharide using recombinant Alg1 and Alg2 MTases, and a synthetic phytanyl pyrophosphate GlcNAc2 (GN2-PP-Phy) substrate\textsuperscript{25,45}. In those studies, M3GN2-PP-Phy was sequentially synthesized with recombinant His-tagged \textit{S. cerevisiae} Alg1 lacking its transmembrane domain (TMD) (Alg1\textsubscript{ΔTM}) to produce M1GN2, and full length Alg2, including its TMD and an N-terminal thioredoxin tag (Trx-Alg2) to produce M3GN2. The Alg2 reaction was performed in the presence of \textit{E. coli} membrane fraction\textsuperscript{25,45}. To produce M5GN2-PP-Phy, we purified Alg11, which adds the next two mannoses on M3GN2-PP-Phy. \textit{S. cerevisiae} Alg11 lacking its N-terminal TMD was overexpressed and purified from \textit{E. coli} (Supplementary Figure 1a and 1b). GN2-PP-Phy and GDP-Man were incubated sequentially with recombinant Alg1\textsubscript{ΔTM}, Trx-Alg2, and Alg11\textsubscript{ΔTM}, to produce M5GN2-PP-Phy (Figure 2a). The reactions were quenched by addition of acid to release PP-Phy from the oligosaccharides, which were purified and analyzed by ultra-performance liquid chromatography-mass spectroscopy (UPLC-MS). Without added MTase, acid hydrolyzed GlcNAc2 (GN2) eluted in two peaks (5.7 and 6.1 min, Figure 2b) designated the alpha and beta anomeric isomers of GN2\textsuperscript{45}. Addition of different combinations of Alg1\textsubscript{ΔTM}, Alg2, and Alg11\textsubscript{ΔTM} resulted in a loss of GN2 and a shift in the UPLC retention time of higher molecular weight glycan products (detected by MS) (Supplementary Figure 2). In the sequential reactions, the first mannose was added by Alg1\textsubscript{ΔTM} to produce the trisaccharide M1GN2; addition of Trx-Alg2 with membrane fraction of \textit{E. coli} (since the bilayer formation is critical for Alg2 \textit{in vitro} activity\textsuperscript{25}, membranes are always included with Trx-Alg2) to the first reaction extended M1GN2 with two additional mannoses, leading to M3GN2; final addition of Alg11\textsubscript{ΔTM} produced M5GN2, which eluted in two peaks that originated from the target product, with retention times at about 14 min in UPLC (Figure 2b).

\textit{In vivo}, Alg1, Alg2 and Alg11 form a multimeric MTase complex on the cytosolic face of the ER membrane\textsuperscript{42}. Assembly of this complex is required for catalysis of the five sequential mannosylations that lead to M5GN2\textsuperscript{46,47}. In an attempt to simplify enzymatic M5GN2 production, we tested if
co-expression of recombinant Alg1ΔTM, Trx-Alg2 and Alg11ΔTM could form an active complex in purified *E. coli* membranes. If so, membrane fractions from *E. coli* containing this complex would enable one-pot mannosylation of GN2-PP-Phy to produce M5GN2-PP-Phy. Membrane fractions isolated from *E. coli* expressing these enzymes and lysed by sonication were analyzed by western blotting. The result demonstrated that when co-expressed, Alg1ΔTM, Trx-Alg2 and Alg11ΔTM in membranes prepared from *E. coli* (see Methods) migrated with a molecular weight indistinguishable from the corresponding proteins purified individually (Supplementary Figure 1c). This Alg1ΔTM, Trx-Alg2 and Alg11ΔTM-containing membrane fraction was incubated with GN2-PP-Phy and GDP-Man. After 12 h, the reaction was quenched and acid-released oligosaccharides were analyzed by UPLC-MS. The result of this experiment suggested that M5GN2 could indeed be produced in a one-pot reaction since GN2-PP-Phy was completely converted to M5GN2 (Figure 2c), with a product yield of ~8 μg from 100 μL reaction volume.

All oligosaccharides generated by above reactions were confirmed by mass spectral analysis (Supplementary Figure 2). To further determine the mannoside linkages of these M5GN2 glycans, we performed the treatment with specific mannosidases (Supplementary Figure 3). *In vivo*, Alg1 attaches the first mannose to GN2-PP-Dol via an β1,4 linkage; Alg2 adds the second mannose via an α1,3 linkage and the third mannose via an α1,6 linkage (Figure 1); Alg11 adds the fourth and fifth mannoses via an α1,2 linkage on the A-arm. If each of the mannoses in M5GN2 generated by above reactions is linked in the way they are *in vivo*, treatment with α1,2 mannosidase removes two α1,2 mannoses modified by Alg11ΔTM; treatment with α1,2-3 mannosidase removes two α1,2 mannoses modified by Alg11ΔTM and one α1,3 mannose modified by Trx-Alg2; treatment with α1,2-3- and α1,6 mannosidase will remove two α1,2 mannoses modified by Alg11ΔTM, one α1,3 mannose and one α1,6 mannose modified by Trx-Alg2. It should be noticed that, in our study, the usual structures of LLOs are abbreviated as MxGN2, in which x indicates the number of Man residues. On the other hand, the nomenclature for those unusual and digested LLO intermediates, which will appear in the late part of the manuscript, be abbreviated as Mx(Ay/By/Cy)GN2, in which A/B/C indicates the A-, B-, or C-arm respectively; y is the number for denoting Man residues disconnected from an particular arm of the M9GN2. All these
structures of LLOs discussed in our study and their abbreviations have been summarized in Supplementary Table 1.

As shown in Supplementary Figure 3, digestion of M5GN2 with α1,2-mannosidase yielded M3GN2 as predicted for its removal of two α1,2 mannoses from the A-arm; α1,2-3-mannosidase digestion removed two α1,2-linked mannoses and one additional α1,3-linked mannose to give M2AGN2; treating with α1,2-3- and α1,6 mannosidase generated M1GN2. These structural analyses demonstrated the M5GN2-PP-Phy synthesized in vitro has the same glycan structure as that synthesized in vivo by the LLO pathway. A scale-up of one-pot reaction produced milligram quantities of the product, whose structure was also verified by mass analysis and NMR spectrum (see in Supplementary Note 1-3, Supplementary Figure 4a and 5a). Therefore, membrane fractions from E. coli that co-express yeast Alg1, Alg2 and Alg11 proteins provide a simple, inexpensive source of enzymes for chemoenzymatic synthesis of M5GN2 with 100% conversion rate.

Synthesis of M9GN2 and its intermediates from M5GN2-PP-Phy

In vivo, after its synthesis on the cytosolic face of the ER, M5GN2-PP-Dol is translocated and extended to M9GN2 by the luminal Alg3, Alg9, and Alg12 MTases (Figure 1)3. Alg3 attaches the sixth mannose to M5GN2-PP-Dol via an α1,3 linkage on the B-arm (Figure 1)27,30; Alg9 adds the seventh mannose via an α1,2 linkage on the B-arm (Figure 1)28; Alg12 adds the eighth mannose via an α1,6 linkage on the C-arm29,48; Alg9 also adds the ninth mannose via an α1,2 linkage on the C-arm (Figure 1)28.

To perform the M5GN2 to M9GN2 extension reactions in vitro (Figure 3a), recombinant yeast Alg3, Alg9 and Alg12 were purified from E. coli. All these enzymes contain multiple transmembrane domains (TMHMM Server v. 2.0), which suggested that their expression in bacteria could be problematic. Indeed, attempts to express N-terminally His-tagged proteins were successful only for Alg12; both Alg3 and Alg9 were unstable in E. coli. Protein stability was improved dramatically by attaching a Mistic-tag to the N-terminus of Alg3 and Alg9. Mistic is a short bacterial protein used to enhance expression of integral membrane proteins in E. coli49. Expression of Mistic-Alg3, Mistic-Alg9 as well as Alg12 was confirmed.
by western blotting (Supplementary Figure 1d). Since detergent extraction of these enzymes from *E. coli*
membrane led to decrease of activity, mannosylation reactions to extend M5GN2 to M9GN2 were
performed with membrane fractions from *E. coli* expressing recombinant Alg3, Alg9 and Alg12.

Since the nucleotide sugar donor GDP-Man cannot cross the ER membrane, luminal ER MTases,
Alg3, Alg9 and Alg12 utilize lipid-linked Man-P-Dol as sugar donor (Figure 1). Purification of
Man-P-Dol is laborious, therefore we tested the feasibility of using another sugar donor more amenable
to *in vitro* mannosylation. Since MTases recognize and extend phytanyl-linked glycan as efficiently as
dolichol-linked glycan substrates\(^{50,51}\), we reasoned that recombinant Alg3, Alg9 and Alg12 might be
able to use phytanyl- instead of dolichol-linked mannose (Man-P-Phy) as a sugar donor. Man-P-Phy is
soluble so if this idea were correct, preparation of sugar donor for these *in vitro* reactions would be
simplified. To test this idea, recombinant *S. cerevisiae* Dpm1\(^{31}\), which catalyzes addition of mannose
from GDP-Man to dolichyl phosphate (P-Dol), was purified from *E. coli* and used to synthesize
Man-P-Phy (Supplementary Figure 6a and 6b). Purified Dpm1 was incubated with GDP-Man and
phytanyl phosphate (P-Phy), and Man-P-Phy production was monitored by thin layer chromatography
(TLC). As shown in Supplementary Figure 6c, almost quantitative conversion of Man-P-Phy from P-Phy
was observed, demonstrating efficient recognition of P-Phy by Dpm1. Man-P-Phy prepared by Dpm1
was used as sugar donor for extension of M5GN2 to M9GN2 by recombinant Alg3, Alg9, and Alg12.

To produce M6GN2-PP-Phy, M5GN2-PP-Phy was incubated with *in situ* prepared Man-P-Phy and a
membrane fraction purified from *E. coli* expressing Mistic-Alg3. After 12 h, acid-hydrolyzed glycan
products were analyzed by UPLC-MS. These glycan products eluted in a peak at ~15.4 min with a mass
m/z: of 1420.19 ([M6GN2+Na]\(^+\)), which corresponds to the predicted molecular weight of M6GN2
(Figure 3b and 3c). To determine the mannose linkage in M6GN2, it was subjected to treatment with
specific mannosidases. *In vivo*, Alg3 attaches one mannose to M5GN2 via an \(\alpha 1,3\) linkage. As shown in
Figure 4a, after digesting the product with \(\alpha 1,2\)-mannosidase, peaks corresponding to M2AGN2 were
observed, suggesting two \(\alpha 1,2\)-linked mannoses and two \(\alpha 1,3\)-linked mannoses were removed; treatment
with \(\alpha 1,2\)-mannosidase resulted in M4A2BC2GN2, indicating the removal of two \(\alpha 1,2\)-linked mannoses.
These results demonstrated that Alg3-catalyzed mannose on M6GN2 bears the predicted \(\alpha 1,3\)-mannoside
linkage. To gain information about the kinetics of this reaction, time-dependent conversion ratios were calculated by measuring the production of M6GN2 at different time points. After 4 h of incubation, the conversion ratio of reaction reached over 90%; by 12 h it had reached ~100% (Supplementary Figure 7a). Thus, we chose 12 h incubation for performing the complete extension of M6GN2-PP-Phy from M5GN2-PP-Phy (Figure 3b).

M7GN2-PP-Phy was produced by sequential addition of two mannoses to M5GN2-PP-Phy by Alg3 and Alg9. M5GN2-PP-Phy was incubated with membrane fractions from *E. coli* expressing Mistic-Alg3 for 12 h, after which Mistic-Alg9 added for an additional 12 h. The molecular weight and anomeric structure of the glycan products were verified by UPLC-MS and mannosidase digestion. Peaks eluting at ~15.9 min in UPLC possessed the mass peak m/z: 1582.54 ([M7GN2+Na]^+), which correspond to M7GN2 (Figure 3b and 3c). After treatment with α1,2-mannosidase, peaks corresponding to M4A2BC2GN2 were observed (Figure 4b), indicating the removal of three α1,2-linked mannoses. These data demonstrated that the seventh Alg9-catalyzed mannose in M7GN2 is attached to M6GN2 by an α1,2-Man linkage. The 12 h incubation time used for Mistic-Alg9 extension in Figure 3b was determined on a kinetic analysis of time-dependent conversion ratios (Supplementary Figure 7b), which revealed nearly 100% conversion from M6GN2 to M7GN2 after 12 h.

M8GN2-PP-Phy was produced by addition of one mannose to M7GN2-PP-Phy by Alg12. After producing M7GN2-PP-Phy with Mistic-Alg3 and Mistic-Alg9, the reaction was stopped by heating at 100 °C to inactivate Alg3 and Alg9, cooled and then incubated with a membrane fraction from *E. coli* producing Alg12 for 12 h. Glycans produced in this reaction of eluted in UPLC-MS peaks with m/z: 1744.30, which corresponds to the predicted mass of M8GN2 (Figure 3b and 3c). To confirm the newly formed Alg12-catalyzed Man-Man linkage in M8GN2 is identical to the *in vivo* α1,6-linked man, the product was subjected to mannosidase treatment. As shown in Figure 4c, digestion of the product with α1,2-3-mannosidase removed two α1,2-linked mannoses from the A-arm, one α1,2-linked mannose from the B-arm, and two additional α1,3-linked mannoses (from A-arm and B-arm, respectively) to generate M3A3B2CGN2 with two α1,6 mannoside linkages on C arm. Further treatment with α1,6 mannosidase removed both these mannoses (Figure 4c). These results demonstrated that the eighth mannose added by
Alg12 is attached via the predicted $\alpha_{1,6}$-linkage. Kinetic analysis of recombinant Alg12 demonstrated it could convert about 80% of M7GN2-PP-Phy to M8GN2-PP-Phy after 8 h of incubation (Supplementary Figure 7c). In contrast, within 8 h both Mistic-Alg3 and Mistic-Alg9 completed conversion reactions, indicating a slower reaction rate of Alg12 compared to the other two MTases (Supplementary Figure 7). In yeast, Alg12 is N-glycosylated on one or more asparagines. Therefore, the weaker kinetic property of Alg12 may be attributed to its lack of N-glycan resulting from expression in *E. coli*.

Alg9 is predicted to add both the seventh and ninth $\alpha_{1,2}$-linked mannoses of M9GN2-PP-Phy. *In vitro* extension of M9GN2 was performed by sequentially incubating M5GN2-PP-Phy with membrane fractions from *E. coli* expressing Mistic-Alg3, Mistic-Alg9 and Alg12. M5GN2-PP-Phy was incubated with membrane fractions from *E. coli* expressing Mistic-Alg3 for 12 h, after which Mistic-Alg9 added for an additional 12 h, then sequentially incubated with membrane fractions containing Alg12 and Mistic-Alg9 for 12 h, respectively. Peaks eluting at ~17.2 min showed an m/z value of 1906.55, assignable as [M9GN2+Na]$^+$ in accord with the calculated molecular weight of M9GN2 (1883.67) (Figure 3b and 3c). These data demonstrated that these sequential reactions produced M9GN2 from M5GN2 with a high conversion rate (88.6%) (Figure 3b). Analysis of mannose linkages of M9GN2 was performed with linkage-specific mannosidases. As shown in Figure 4d, treatment of M9GN2 with $\alpha_{1,2}$-mannosidase yielded M5A2BCGN2, as predicted for removal of two $\alpha_{1,2}$ mannoses from the A-arm, one $\alpha_{1,2}$-linked mannose from the B-arm, and one $\alpha_{1,2}$-linked mannose from the C-arm. Similarly, $\alpha_{1,2}$-3-mannosidase digestion removed four $\alpha_{1,2}$-linked mannoses and two additional $\alpha_{1,3}$-linked mannoses (from A-arm and B-arm, respectively) to generate M3A3B2CGN2 with two $\alpha_{1,6}$ mannoside linkages on C arm. Peaks corresponding to M1GN2 were observed after treatment with $\alpha_{1,2}$-3 and $\alpha_{1,6}$ mannosidases, the latter removing two additional $\alpha_{1,6}$ mannoses. Further treatment with $\beta$-mannosidase hydrolyzed the last $\beta_{1,4}$-linked mannose, leaving GN2 as the sole product (Figure 4d). Taken together, these results demonstrated unequivocally that M9GN2 bearing four $\alpha_{1,2}$-man, two $\alpha_{1,3}$-man, two $\alpha_{1,6}$-man and one $\beta_{1,4}$-man was successfully reconstituted *in vitro*, and its structure is identical to that produced *in vivo*.

To efficiently synthesize the M9GN2 glycan from M5GN2-PP-Phy, a one-pot reaction was attempted. Membrane fractions prepared from *E. coli* expressing Mistic-Alg3, Mistic-Alg9 and Alg12 were mixed.
together and incubated with M5GN2-PP-Phy for 20 h. After acid hydrolysis, reaction products were subjected to UPLC-MS analysis. As shown in Figure 3d, UPLC peaks corresponding to M5GN2 substrate (eluting at around 14.8 min) were completely converted to product in a single peak eluting at ~17.3 min. This one-pot reaction converted 100% of M5GN2 to M9GN2, an efficiency higher than that of its stepwise synthesis (Figure 3c and 3d). The reason for this difference in yield was not further examined. Nevertheless, these results demonstrate the successful in vitro synthesis of M9GN2 with near complete yield, with a product yield of ~12 μg from 100 μL reaction volume. When scaled-up, this reaction gave milligram quantities of the product, whose structure was verified by mass analysis and NMR spectrum (see Supplementary Note 1-3, Supplementary Figure 4b, 5b-d).

**Alg MTases display strict substrate specificity**

There is strong genetic evidence to support the model that the strict substrate specificity of each Alg GTase leads to ordered assembly of LLO glycans. Our in vitro system provided an opportunity to rigorously test the specificity of each Alg MTases by varying the order of addition of each enzyme in the presence of different substrates.

The cytosolic Alg MTases catalyze all the cytosolic-facing ER reactions. Among them, Alg1 is known to be responsible for the addition of a β1,4-linked mannose to GN2-PP-Phy. To determine if Alg2 or Alg11 could also use GN2-PP-Phy as substrate, Trx-Alg2 and Alg11ΔTM were incubated in the reaction buffer with GN2-PP-Phy and GDP-Man. Reaction products were analyzed after hydrolysis by UPLC-MS. As shown in Figure 5a, in the absence of Alg1, no mannosylation product was detected, indicating that neither Trx-Alg2 nor Alg11ΔTM could recognize GN2 as the substrate. When Alg1ΔTM and Alg11ΔTM were incubated with GN2-PP-Phy and GDP-Man in the absence of Trx-Alg2, Alg1ΔTM extended GN2 to M1GN2, but M1GN2 was not further mannosylated by Alg11ΔTM (Figure 5a). This result demonstrated that Alg11 could not recognize M1GN2-PP-Phy as its substrate. Taken together, these data demonstrate recombinant Alg1ΔTM, Trx-Alg2 and Alg11ΔTM each showed the capacity to distinguish the corresponding acceptor structures from other intermediates.

Similar order of addition experiments was performed with Alg3, Alg9 and Alg12, which catalyze the
luminal reactions to produce M9GN2 from M5GN2. Extension of M5GN2 was performed in the
presence of M5GN2-PP-Phy and Man-P-Phy, along with different combinations of Alg 3, Alg9, and
Alg12. Reaction products were analyzed after hydrolysis by UPLC-MS (Figure 5b). We found that in
the absence of Alg3, neither Alg9 nor Alg12 could add any mannoses to M5GN2-PP-Phy. In the absence
of Alg9, even after Alg3 extended M5GN2 to M6GN2, Alg12 could not add any additional mannoses to
it (Figure 5b). These results implied that Alg9 and Alg12 each are capable of recognizing only the
product of preceding Alg in the LLO pathway. Consistent with in vivo specificity studies\textsuperscript{29,53}, our results
demonstrated that each of the recombinant Alg proteins display strict substrate specificity, and it is this
substrate specificity that dictates the strict order of LLO mannosylation.

### Synthesis of non-physiological LLOs

Another notable observation was the absence of unusual non-physiological oligosaccharide products
in these in vitro reactions. In vivo, LLO synthesis is compartmentalized in the cytosol and lumen. These
two topologically distinct reaction stages are bridged by a flippase that translocates M5GN2-PP-Dol
across the membrane from the cytosol to the ER lumen (Figure 1). Because of these topological
constraints, MTases whose catalytic domains reside in the ER lumen or in the cytosol are exposed to
only a subset of LLO intermediates in vivo. That is, cytosolic LLO intermediates are not found in the ER
lumen and vice versa. Our in vitro two-pot reactions mimicked these constraints by physically separating
the Alg1, Alg2 and Alg11 reactions from those of Alg3, Alg9, and Alg12. Thus, one explanation for the
absence of unusual glycan byproducts is that their synthesis is simply prevented by
compartmentalization of enzymes. If this is correct, luminal enzymes should be able to extend cytosolic
intermediates if they are available. To test this idea, cytosolic LLOs, including GN2-PP-Phy, M1GN2-PP-Phy, M3GN2-PP-Phy and an intermediate M2GN2-PP-Phy
(Man-(\(\alpha_1,3\))-Man-GlcNAc2-PP-Phy) generated by an Alg2 mutant (G257P) that accumulates M1GN2
and M2GN2 were prepared\textsuperscript{25}. These intermediates were incubated with recombinant Alg3, Alg9, and Alg12, and glycan products analyzed by UPLC-MS. In the presence of Mistic-Alg3, Mistic-Alg9 and Alg12, neither GN2-PP-Phy, M1GN2-PP-Phy nor M2GN2-PP-Phy was elongated (Figure 6a). In
contrast, a significant amount of M3GN2-PP-Phy was elongated by Alg3 to produce M4A2BC2GN2 (Figure 6b). Two groups of peaks could be detected by UPLC-MS. As confirmed by MS, glycans in the first group eluted ~ 12.7 min and were derived from M3GN2-PP-Phy while glycans in the second group of peaks eluted at about 13.7 min and were derived from M4A2BC2GN2 (Supplementary Figure 8a). Sequential addition of Mistic-Alg3 and Mistic-Alg9 converted M3GN2-PP-Phy to M5A2C2GN2-PP-Phy. In contrast, incubation of M3GN2 with both Mistic-Alg9 and Alg12 failed to produce any additional products. These results suggested that extension of M3GN2-PP-Phy to M5A2C2GN2-PP-Phy requires successive and ordered mannosylation by Alg3 and Alg9. This idea was verified since a reaction that included M3GN2 incubated sequentially with Mistic-Alg3 for 12 h, followed Mistic-Alg9 for another 12 h, followed by Alg12 for another 12 h, produced M7AGN2 (Figure 6b). The acid-hydrolyzed glycan products were analyzed by UPLC-MS (Supplementary Figure 8a). To confirm the structures of these unusual LLOs, the final product M7AGN2 was treated with specific mannosidases (Supplementary Figure 8b). Our results confirmed that all the additional mannoses added on M3GN2 in M7AGN2 derived from the ordered mannosylation by Alg3, Alg9 and Alg12. Therefore, we concluded that M3GN2 can serve as the substrate of ER luminal MTases in vitro for production of several unusual LLOs bearing high-mannose type glycans (Supplementary Table 1).

**Discussion**

In this study, we describe in vitro reconstitution of the eukaryotic LLO pathway from GN2 to M9GN2, using recombinant Alg MTases. Reconstitution involved two successive one-pot reactions, which correspond to the in vivo cytosolic and luminal reactions. First, five mannoses were added to GN2 by recombinant Alg1, Alg2 and Alg11 to produce M5GN2. This M5GN2 then served as the substrate for extension by recombinant Alg3, Alg9 and Alg12 to produce M9GN2. These two sequential one-pot reactions produced an M9GN2 oligosaccharide whose mannose linkages were verified to be identical to that produced in vivo.

*In vitro* synthesis of M5GN2 was first described by Locher and co-workers using yeast Alg1, Alg11, and human Alg2 expressed and purified from mammalian cells. While this method provides proof of
principle, it is impractical as general strategy for M5GN2 production because of its low yield as well as the high cost of preparing human Alg2. We previously described purification of active, recombinant yeast Alg2 from *E. coli* and built on that approach for M5GN2 synthesis in the present study. Mannosylation of GN2-PP-Phy by purified Alg1ΔTM, Trx-Alg2 and Alg11ΔTM to produce M5GN2-PP-Phy was extremely efficient, with a conversion rate approaching 100% (Figure 2b). Alg1, Alg2 and Alg11 associate *in vivo* and we discovered they also do so in *E. coli* when co-expressed. This property was exploited to develop a one-pot reaction to mannosylate GN2-PP-Phy to M5GN2-PP-Phy, with a membrane fraction from *E. coli* that simultaneously over-expressed recombinant Alg1, Alg2 and Alg11 as a source of enzymes (Figure 2c). This co-expression system is important because it significantly simplifies M5GN2-PP-Phy synthesis *in vitro.*

Assembly of M9GN2-PP-Dol from M5GN2 occurs in the ER lumen, and genetic evidence has implicated Alg3, Alg9 and Alg12 as the GTases responsible for these activities. Our experiments showing that recombinant Mistic-Alg3, Mistic-Alg9 and Alg12 were both necessary and sufficient to extend M5GN2 to M9GN2 provide direct evidence for their activities, which has thus far been lacking (Figure 3 and 4). Furthermore, the substrate specificity of each of these MTases was studied by adding different combinations of Alg proteins to the substrate (Figure 5). Our results not only provided direct evidence that Alg3, Alg9 and Alg12 are the luminal MTases that elongate M5GN2 to M9GN2 during LLO biosynthesis *in vivo,* but also verified the strict substrate specificity of their MTase activities at enzyme level (Figure 5b).

Overexpression of Alg12 in an *alg9A* strain accumulates similar levels of M6GN2 and M7BCGN2 N-glycans *in vivo,* indicating that the second α1,6-man (Figure 1) can be directly added to the M6GN2 structure even in the absence of Alg9 *in vivo.* We did not observe such a direct modification on M6GN2 by recombinant Alg12 *in vitro* under standard conditions (Figure 5b). However, addition of a 5-fold excess of Alg12 coupled with a much longer incubation time (to over 48 h) allowed detection of a small amount of product (Supplementary Figure 9a). This product was isolated and analyzed by UPLC-MS, and treated with a series of linkage-specific mannosidases as described above (Supplementary Figure 9b, 9c). These experiments confirmed this product as M7BCGN2, which has an
additional α1,6-man on the C arm of M6GN2. One explanation for the apparent difference between the
in vivo and in vitro reactions may be due to a more robust activity of N-glycosylated Alg12 produced in
a eukaryote compared to recombinant Alg12 from E. coli (Supplementary Figure 7c) that lacks
N-glycan(s).

Interestingly, stepwise synthesis of M9GN2 using Mistic-Alg3, Mistic-Alg9 and Alg12 from
membrane fractions converted less than 90% of M5GN2-PP-Phy to M9GN2-PP-Phy (Figure 3b), while
the one-pot reaction with membranes showed ~100% conversion. This suggests that these luminal
MTases work better when simultaneously mixed. The cytosolic-facing Alg1, Alg2 and Alg11 MTases
(Figure 2c) work as a multimeric complex in vivo and it is tempting to speculate that the luminal Alg3,
Alg9 and Alg12 may physically interact with one another as well. This physical interaction would be
facilitated in the one pot reaction, which in turn may promote the higher efficiency we observe in vitro.
Further experiments are required to test if Alg3, Alg9 and Alg12 form complexes in vivo or in vitro.

In vivo, M3GN2-PP-Dol cannot gain access to the ER lumen. This creates a topological constraint that
prevents the luminal Alg3, Alg9, and Alg12 from potentially producing aberrant LLO products. When
M3GN2-PP-Phy was incubated with recombinant Alg3, we observed a moderate yield of
M4A2BC2GN2 glycan (Figure 6b), suggesting that the two Alg11-catalyzed α1,2-mannose on the A
arm are not critical ligands required for glycan recognition by Alg3. Further mannosylation of
M4A2BC2GN2 by Alg9 produced M5A2C2 glycan, and the combination of Alg3, Alg9 and Alg12
resulted in M7AGN2 (Figure 6b). Interestingly, incubation with the combination of Alg3, Alg9 and
Alg12 somehow increased the conversion rate of Alg3, leading to the accumulation of M6A2CGN2 and
M7AGN2. alg11Δ yeast mutants have been reported to accumulate some unusual LLO with six or seven
mannoses, but how or why this happens has been a mystery. Our results provide an explanation of
this phenomenon. alg11Δ mutants accumulate high levels of M3GN2-PP-Dol. This may favor the
occasional translocation of M3GN2 into the ER lumen, which in turn could provide the M3GN2-PP-Dol
substrate for elongation by Alg3, Alg9 and Alg12 to produce aberrant luminal LLOs. The ability to
produce these unusual high-mannose glycans, such as M7AGN2 (Supplementary Table 1), may be
useful for biochemical studies that will provide a deeper understanding of the substrate specificity of
Scaling-up these two one-pot reactions produced milligram quantities of products, which are sufficient for performing further bioassays. M9GN2 is a crucial glycan intermediate in the N-linked glycosylation pathway as the substrate for downstream enzymes involved in its transfer to protein and further modification. Thus, our study provides an important tool for biochemical studies of the mechanism and structure of those downstream enzymes.

Methods

Plasmid Constructions

All expression plasmids were constructed such that each encoded Alg protein contained an N-terminal His6 tag. pET28-Alg1ΔTM and pET32-Trx-Alg2 have been described. The Mistic gene, was synthesized (BGI, Shenzhen, China) and cloned into the Ndel and Nhel sites of pET28 (Thermo Scientific, MA, USA), generating pET28-Mistic. Yeast genes encoding Alg11ΔTM (aa 45-548), Dpm1, Alg3, Alg9 and Alg12 were amplified by PCR using genomic DNA of S. cerevisiae. ALG11ΔTM, DPM1 and ALG12 were cloned into vector pET28. ALG3 and ALG9 were cloned into pET28-Mistic. Oligonucleotide primers are listed in Supplementary Table 2. Expression plasmids, including their description, parent plasmid, and cloning sites are listed in Supplementary Table 3. Plasmid sequencing data are provided as Supplementary Data 1. To construct the Alg1, Alg2, Alg11 co-expression plasmid (pET28-Alg1ΔTM-Trx-Alg2-Alg11ΔTM), ALG1ΔTM, TRX-ALG2 and ALG11ΔTM were amplified by PCR from pET28-Alg1ΔTM, pET32-Trx-Alg2 and pET28-Alg11ΔTM, and sequentially cloned into Ncol and BamHI, SacI and EcoRI, NotI and Xhol sites of one pET28 vector, respectively. Insertion of 5’ T7 promoter and ribosome binding sites in front of both TRX-ALG2 and ALG11ΔTM genes allowed their simultaneous expression.

Protein expression and purification

All proteins used in this study contained an N-terminal His6-tag. Overexpression of Alg1ΔTM, Trx-Alg2, Alg11ΔTM, Dpm1, Mistic-Alg3, Mistic-Alg9, Alg12, and the co-expression of Alg1ΔTM,
Trx-Alg2 and Alg11ΔTM were performed in *E. coli* Rosetta (DE3) cells originating from BL21 (Thermo Scientific, MA, USA, Catalogue Number: 70-954-4). Cells were cultured in Terrific-Broth (TB, 1.2% tryptone, 2.4% yeast extract, 0.5% glycerol, 17 mM KH₂PO₄ and 72 mM K₂HPO₄) at 37 °C until the OD₆₀₀ was between 0.8 and 1.2. Cultures were cooled to 16 °C prior to induction with isopropyl-β-D-thiogalactopyranoside (IPTG, Sangon Biotech, Shanghai, China). IPTG was added to a final concentration of 0.1 mM to induce T7-dependent gene expression. Cultures were induced overnight with shaking at 16°C. After induction, cells were harvested and resuspended in buffer A [25 mM Tris/HCl (pH 8.0) and 150 mM NaCl], then disrupted by sonication on ice to produce a lysate that was further processed as described below.

Dpm1 was purified using the same method as previously described for purification of Alg1ΔTM and Trx-Alg2²⁵⁻⁴⁵. Briefly, the cell lysate was spun down to remove cellular debris (4,000 × g, 20 min, 4 °C), followed by pelleting of insoluble materials containing *E. coli* membrane (20,000 × g, 90 min, 4 °C). Proteins in the insoluble fraction were solubilized for 1 h in buffer A containing 1% Triton X-100. His-tagged Dpm1 was purified from the detergent-soluble fraction with HisTrap HP affinity chromatography (GE Healthcare, Buckinghamshire, UK). Alg11ΔTM was purified as followed. The cell lysate was spun down to remove cellular debris and insoluble material (12,000 × g, 30 min, 4 °C). Alg11ΔTM in the supernatant was purified using HisTrap HP affinity chromatography. The purified protein was dialyzed against buffer [25 mM Tris-HCl (pH 8.0), 50 mM NaCl], followed by concentration using Amicon Ultra 10K NMWL filtration units (Millipore, MA, USA). Protein concentration was determined with the BCA assay kit (Sangon Biotech, Shanghai, China).

To prepare membrane fractions from *E. coli* expressing recombinant proteins, the cell lysate was spun down to remove cellular debris (4,000 × g, 20 min, 4 °C), followed by pelleting of the membranes (100,000 × g, 60 min, 4 °C). For Mistic-Alg3, Mistic-Alg9 and Alg12, membranes were homogenized in [14 mM MES/NaOH (pH 6.5), 30% glycerol]; for co-expressed Alg1ΔTM, Trx-Alg2 and Alg11ΔTM, membranes were homogenized in [50 mM Tris/HCl (pH 7.5), 30% glycerol]. The membrane fractions were stored at -20 °C. Enzyme activity in membranes remained active for at least three months.

Protein expression was verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting (Supplementary Figure 1). Protein samples were boiled for 5 min at 100 °C before loading. Typically, 10 µg of protein samples were separated by 10% or 12% SDS-PAGE, followed by coomassie brilliant blue staining. For western blotting, samples were transferred onto polyvinylidenedifluoride membranes (Bio-Rad, CA, USA), incubated with anti-His mouse mAb (1:2,000) (Code number: HT501, Lot number: M21022, TransGen Biotech, Beijing, China), followed by goat anti-mouse IgG, HRP (1:5,000) (Code number: H5201-01, Lot number: M21015, TransGen Biotech, Beijing, China) and detected by chemiluminescence (ECL, Bio-Rad, CA, USA).

**Preparation of phytanyl phosphate mannose with Dpm1**

Chemo-enzymatic synthesis of phytanyl phosphate mannose (Man-P-Phy) was performed as reported. Briefly, standard reaction mixtures contained 50 mM Tris/HCl (pH 7.5), 10 mM MgCl₂, 1% NP-40, 20 mM P-Phy, 50 mM GDP-Man (Sigma-Aldrich, MO, USA), and 2 mg/mL purified Dpm1 in a total volume of 50 µL. The reaction was performed at 30 °C for 10 h, Dpm1-dependent mannose transfer efficiency from GDP-Man to P-Phy was monitored by thin layer chromatography using Merck 60 F₂₅₄ silica-coated plates (Millipore, MA, USA) with a chloroform/methanol/water (6.5:3.5:0.4, V/V) solvent and developed in ethanol/sulphuric acid (19:1, V/V) with heating. The conversion yield of P-Phy to Man-P-Phy was estimated by comparing the newly formed product spot with P-Phy. This reaction mixture was directly added into MTase reactions without further treatment.

**Enzymatic assembly of M1~9GN2-PP-Phy**

The chemical synthesis of GN2-PP-Phy was prepared as reported. All enzyme assays were performed in the following buffer: [14 mM MES/NaOH (pH 6.0), 4 mM potassium citrate, 10 mM MgCl₂, 10 mM MnCl₂, 0.05% NP-40, 50 µM GN2-PP-Phy, 1 M sucrose; 2 mM GDP-Man] in a total volume of 100 µL. For assembly of the M5GN2-PP-Phy, purified enzymes [Alg1ΔTM (0.5 µg/mL), Trx-Alg2 (150 µg/mL) and Alg11ΔTM (50 µg/mL)] were added stepwise and incubated at 30 °C for 12 h (each); Reactions performed with membrane fractions from *E. coli* that co-expressed Alg1ΔTM, Trx-Alg2 and Alg11ΔTM (20 µg/mL) were incubated at 30 °C for 12 h.
For stepwise assembly of M9GN2-PP-Phy from M5GN2-PP-Phy, membrane fractions from *E. coli*
expressing [Mistic-Alg3 (20 mg/mL), Mistic-Alg9 (20 mg/mL) and Alg12 (20 mg/mL)] were added
stepwise and incubated at 30 °C for 12 h with 2 mM Man-P-Phy. For one-pot synthesis of
M9GN2-PP-Phy from M5GN2-PP-Phy, these membrane fractions were incubated simultaneously with 2
mM Man-P-Phy at 30 °C for 20 h, rather than sequentially.

**Mannosidase digestions**

Digestion of glycans (2.5 nmol) with 3.2 U of α1,2-3-mannosidase (*Xanthomonas manihotis*, New
England Biolabs, MA, USA), 4 U of α1,6-mannosidase (*Xanthomonas manihotis*, New England Biolabs)
and 0.1 mU of α1,2-mannosidase (*Aspergillus saitoi*, ProZyme, CA, USA) were performed in 10 μL at
25 °C for 16 h in buffers supplied by the manufacture. Digestion of glycans (2.5 nmol) with 25 mU of
β-mannosidase (*Helix pomatia*, Sigma-Aldrich, MO, USA) were performed in 50 mM sodium citrate
(pH 4.4) at 25 °C for 16 h.

**UPLC-MS analysis of saccharides**

Samples were hydrolyzed with 20 mM hydrogen chloride. After 1 h incubation at 100 °C, the
water-soluble glycan-containing fraction was desalted by solid-phase extraction using 1 mL Supelclean
ENVI-Carb Slurry (Sigma-Aldrich, MO, USA) and lyophilized. Dried samples were dissolved in water
prior to UPLC-MS analysis. Samples were analyzed on a TSQ Quantum Ultra (Thermo Scientific, MA,
USA) coupled to a Dionex Ultimate 3000 UPLC (Thermo Scientific, MA, USA). Glycans were applied
on an Acquity UPLC BEH Amide column (1.7 μm, 2.1 x 100 mm, Waters, MA, USA) and eluted with
an acetonitrile gradient with a flow rate 0.2 mL/min. The gradient program was set as follows; 0-2 min,
isocratic 80% acetonitrile; 2-15 min, 80-50% acetonitrile; 15-18 min, isocratic 50% acetonitrile. Eluent
was monitored by measuring total ions at positive mode in the mass range of m/z 400-2000.

**Data availability**

The source data underlying Supplementary Figures 1a-d, 6b-c and 7a-c are provided as a Source Data
file. A reporting summary for this Article is available as a Supplementary Information file. All other data
that support the results of this study are available from the corresponding authors upon reasonable
request.
References


18. Gao, X. D., Tachikawa, H., Sato, T., Jigami, Y. & Dean, N. Alg14 recruits Alg13 to the cytoplasmic face of the


Author contributions

S.-T. L., T.-T. L, X.-X. X., Y. D., N. W. and X.-D. G. performed experiments and analyzed data. Z. L.
and T. K. provided expertise and feedback. N. W., D. N. and X.-D. G. proposed and supervised the
project and wrote the manuscript. All authors confirmed and edited the manuscript.

Acknowledgements

We thank Drs. Hideki Nakanishi and Morihisa Fujita for discussion. We are grateful to Ms. Yahui Gao
and Ms. Haili Liu for the arrangement of the data collection facilities and to Ms. Xiaohong Gu for
supporting the NMR measurements. This work was supported by grants-in-aid from the National
Natural Science Foundation of China (21778023; 21576118; 31770853; 21807048), the Natural Science
Foundation of Jiangsu Province (BK20170174), Fundamental Research Funds for the Central
Universities (JUSRP51629B, JUSRP11727), Program of Introducing Talents of Discipline to
Universities (No.111-2-06), Collaborative Innovation Center of Jiangsu Modern Industrial Fermentation,
Top-notch Academic Programs Project of Jiangsu Higher Education Institutions and National first-class
discipline program of Light Industry Technology and Engineering (LITE2018-015).

Competing interests

The authors declare that there is no conflict of interest to this work.
**Figure legends**

**Figure 1.** Mannosylation in the eukaryotic LLO biosynthesis pathway. Alg mannosyltransferases (MTases) catalyze formation of M9GN2-PP-Dol by sequentially adding mannoses to GN2-PP-Dol. Cytosolic reactions use the nucleotide sugar GDP-Man donor, while luminal enzymes use Man-P-Dol, synthesized by Dpm1. Linkages of each sugar are indicated on the right, as are the A, B and C arms of the triantennary oligosaccharide.

**Figure 2.** *In vitro* M5GN2-PP-Phy synthesis. (a) Schematic diagram of sequential mannosylation reactions catalyzed by Alg1ΔTM, Trx-Alg2 and Alg11ΔTM. (b) UPLC chromatograms of hydrolyzed glycans from reactions with various combinations of purified MTases. Each segment of sequential reactions was incubated for 12 h, as described in Materials and Methods. Reactions that included GN2-PP-Phy, GDP-Man, and Alg1ΔTM produced M1GN2 (Alg1ΔTM); sequential addition of Alg1ΔTM and Trx-Alg2 produced M3GN2 [(Alg1ΔTM)+Trx-Alg2]; sequential addition of Alg1ΔTM, Trx-Alg2, and Alg11ΔTM generated M5GN2 [(Alg1ΔTM+Trx-Alg2)+Alg11ΔTM]. (c) UPLC chromatogram of hydrolyzed glycans from a one-pot reaction containing GN2-PP-Phy, GDP-Man and a membrane fraction purified from *E. coli* that co-expressed Alg1ΔTM, Trx-Alg2 and Alg11ΔTM.

**Figure 3.** *In vitro* assembly of the M9GN2-PP-Phy. (a) Schematic diagram of sequential mannosylation reactions catalyzed by Mistic-Alg3, Mistic-Alg9 and Alg12. (b) UPLC chromatograms of hydrolyzed glycans from reactions with various combinations of membrane fraction purified from *E. coli* expressing either Alg3, Alg9 or Alg12. In the presence of M5GN2-PP-Phy and Man-P-Phy, addition of Mistic-Alg3 produced M6GN2 (Mistic-Alg3); sequential addition of Mistic-Alg3 and Mistic-Alg9 produced M7GN2 (Mistic-Alg3+Mistic-Alg9); the reaction with Mistic-Alg3 and Mistic-Alg9 was stopped by heating, then adding Alg12 produced M8GN2 [(Mistic-Alg3+Mistic-Alg9)/heat+Alg12]; sequential addition of Mistic-Alg3 for 12 h, Mistic-Alg9 for 12 h, Alg12 for 12 h and Mistic-Alg9 for 12 h generated M9GN2 (Mistic-Alg3+Mistic-Alg9+Alg12). (c) Mass spectra of glycans released from Phy-PP-linked oligosaccharide products. Mass analyses showed the peaks eluted (Figure 3b) at ~15.5 min, ~16.0 min,
~16.6 min and ~17.2 min correspond to M6GN2 ([M6GN2+Na]+), M7GN2 ([M7GN2+Na]+), M8GN2 ([M8GN2+Na]+) and M9GN2 ([M9GN2+Na]+), respectively. (d) UPLC chromatogram of hydrolyzed glycans from reactions in which Mistic-Alg3, Mistic-Alg9 and Alg12 were added simultaneously for 20 h in one pot to generate M9GN2 from M5GN2-PP-Phy and Man-P-Phy.

Figure 4. UPLC-MS analyses of mannosidase digestion of M9GN2 and precursors. Each of the glycans generated in experiments shown in Figure 3b were digested with linkage-specific mannosidases, including: α1,2-mannosidase, which removes terminal α1,2 mannoses; α1,2-3-mannosidase, which removes terminal α1,2 mannoses and terminal α1,3 mannoses; α1,6-mannosidase, which removes terminal non-branched α1,6 mannoses; β-mannosidase, which removes terminal β-mannoses. Digestion products and their deduced structure are depicted schematically (a) Digestion of M6GN2 with α1,2-3-mannosidase produced M2AGN2; while its digestion with α1,2-mannosidase produced M4A2BC2GN2. (b) Digestion of M7GN2 with α1,2-mannosidase produced M4A2BC2GN2. (c) Digestion of M8GN2 with α1,2-3-mannosidase produced M3A3B2CGN2; while its digestion with α1,2-3-mannosidase and α1,6-mannosidase produced M1GN2. (d) Digestion of M9GN2 with α1,2-mannosidase produced M5BCGN2; digestion with α1,2-3-mannosidase produced M3A3B2CGN2; digestion with both α1,2-3-mannosidase and α1,6-mannosidase produced M1GN2; further treatment with β-mannosidase produced GN2.

Figure 5. Substrate specificity of Alg MTases. (a) Substrate specificity of Alg1, Alg2 and Alg11. Reactions contained GN2-PP-Phy and GDP-Man and the indicated combination of Alg1ΔTM, Trx-Alg2 and/or Alg11ΔTM. Glycan products were analysed by UPLC-MS. (b) Substrate specificity of Alg3, Alg9 and Alg12. Each reaction contained M5GN2-PP-Phy and Man-P-Phy and the indicated combination of Mistic-Alg3, Mistic-Alg9 and Alg12. Glycan products were analysed by UPLC-MS. Reaction products are indicated by the arrows, and their deduced structure is depicted schematically

Figure 6. Specificity of the ER luminal MTases for non-physiological substrates. (a) Reactions were
performed in the presence of GN2-PP-Phy, M1GN2-PP-Phy, or a mixture of M1GN2-PP-Phy/M2GN2-PP-Phy, and Man-P-Phy. Products were analyzed by UPLC-MS. Addition of Mistic-Alg3, Mistic-Alg9 and Alg12 (Mistic-Alg3+Mistic-Alg9+Alg12) failed to elongate any of those substrates. (b) Reactions were performed in the presence of M3GN2-PP-Phy and Man-P-Phy. Stepwise addition of the membrane fractions of Mistic-Alg3, Mistic-Alg9 and Alg12 produced a variety of unusual LLOs, whose deduced structure is shown schematically. Addition of Mistic-Alg3 alone generated M4A2BC2GN2 (Mistic-Alg3); sequential addition of Mistic-Alg3 and Mistic-Alg9 generated M5A2C2GN2 [(Mistic-Alg3)+Mistic-Alg9]; sequential addition of Mistic-Alg3, Mistic-Alg9 and Alg12 generated M6A2CGN2 and M7AGN2 [(Mistic-Alg3+Mistic-Alg9)+Alg12]. Products are indicated by the arrows.
P-Phy

Mastic-Alg3

Mastic-Alg9

Alg12

Mastic-Alg9

M5GN2-PP-Phy

M6GN2-PP-Phy

M7GN2-PP-Phy

M8GN2-PP-Phy

M9GN2-PP-Phy

GlcNAc

Phytanol

Man

Mistic-Alg3

Mistic-Alg9

Alg12

Mistic-Alg12

Matic-Alg9

Mistic-Alg3

Mistic-Alg9

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12 + Mistic-Alg9

M5GN2

M6GN2

M7GN2

M8GN2

M9GN2

Relative abundance (%)

Time (min)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

Mistic-Alg3

Mistic-Alg9

Mistic-Alg12

Mistic-Alg3

Mistic-Alg9

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12 + Mistic-Alg9

M5GN2

M6GN2

M7GN2

M8GN2

M9GN2

Relative abundance (%)

Time (min)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

Mistic-Alg3

Mistic-Alg9

Mistic-Alg12

Mistic-Alg3

Mistic-Alg9

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12 + Mistic-Alg9

M5GN2

M6GN2

M7GN2

M8GN2

M9GN2

Relative abundance (%)

Time (min)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

Mistic-Alg3

Mistic-Alg9

Mistic-Alg12

Mistic-Alg3

Mistic-Alg9

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12 + Mistic-Alg9

M5GN2

M6GN2

M7GN2

M8GN2

M9GN2

Relative abundance (%)

Time (min)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

Mistic-Alg3

Mistic-Alg9

Mistic-Alg12

Mistic-Alg3

Mistic-Alg9

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12

(Mistic-Alg3 + Mistic-Alg9)/heating + Alg12 + Mistic-Alg9

M5GN2

M6GN2

M7GN2

M8GN2

M9GN2

Relative abundance (%)

Time (min)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)

\([M6GN2+Na]^+\)

\([M7GN2+Na]^+\)

\([M8GN2+Na]^+\)

\([M9GN2+Na]^+\)